Managing comorbidities in COPD

G Hillas, F Perlikos, I Tsiligianni… - International journal of …, 2015 - Taylor & Francis
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality
worldwide. Age and smoking are common risk factors for COPD and other illnesses, often …

Methods to reduce prescribing errors in elderly patients with multimorbidity

AH Lavan, PF Gallagher… - Clinical interventions in …, 2016 - Taylor & Francis
The global population of multimorbid older people is growing steadily. Multimorbidity is the
principal cause of complex polypharmacy, which in turn is the prime risk factor for …

Association of off-label drug use and adverse drug events in an adult population

T Eguale, DL Buckeridge, A Verma… - JAMA internal …, 2016 - jamanetwork.com
Importance Off-label use of prescription drugs has been identified as an important
contributor to preventable adverse drug events (ADEs) in children. Despite concerns …

Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium

A Nobili, S Garattini, PM Mannucci - Journal of comorbidity, 2011 - journals.sagepub.com
The pattern of patients admitted to internal medicine wards has dramatically changed in the
last 20–30 years. Elderly people are now the most rapidly growing proportion of the patient …

Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions

A Corsonello, C Pedone… - Current medicinal …, 2010 - ingentaconnect.com
Aging is known to be associated with an increased prevalence of multiple chronic diseases,
which frequently causes the use of complex therapeutic regimens. The aging process is …

Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score

G Onder, M Petrovic, B Tangiisuran… - Archives of internal …, 2010 - jamanetwork.com
Background The aim of the present study was to develop and validate a method of
identifying elderly patients who are at increased risk for an adverse drug reaction (ADR) …

VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification

M Wehling, H Burkhardt, A Kuhn-Thiel, F Pazan… - Age and …, 2016 - academic.oup.com
Trial design: to further validate the FORTA (Fit fOR The Aged) concept, a bicentric
randomised, controlled trial was run in two geriatric clinics. Methods: patients (≥ 65 years,≥ …

The clinical implications of ageing for rational drug therapy

S Shi, K Mörike, U Klotz - European journal of clinical pharmacology, 2008 - Springer
Introduction The proportion of the elderly is constantly increasing and by the year 2025 20%
of the population will be above 65 years of age. With advanced age, subjects will develop …

Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use?

G Sergi, MD Rui, S Sarti, E Manzato - Drugs & aging, 2011 - Springer
Polypharmacy is a problem of growing interest in geriatrics with the increase in drug
consumption in recent years, particularly among people aged> 65 years. The main reasons …

Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study

M Zhang, CDAJ Holman, SD Price, FM Sanfilippo… - Bmj, 2009 - bmj.com
Objectives To identify factors that predict repeat admission to hospital for adverse drug
reactions (ADRs) in older adults. Design Population based retrospective cohort study …